Arley Peter, MD
Cardiovascular Disease · Vero Beach, FLNPI 1952515116
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,500 of the $52,572 with a category attached, or 69.4%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 78.3% of it on its own, with 42 other manufacturers making up the rest. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 501 payments — averaging $104.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$41K
- Medtronic$3K
- Abbott$1K
- Boston Scientific$750
- Novartis$555
- Amgen$465
- plus $6K from 37 others
What the payments were for
- Speaking & faculty fees$36,50069%
- Travel & lodging$4711%
- Food & beverage$15,56730%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$36,601
- VenaSeal$921
- ClosureFast$462
- BioMonitor$361
- Reveal LINQ$347
- Xience Sierra Coronary Stent System$217
- Barostim Neo System$145
- Micra$143
- WATCHMAN Access System$142
- SAPIEN 3 Ultra RESILIA$129
- AMPLATZER AMULET$127
- TEGSEDI$125
- Inpefa$125
- Adempas$125
- Wegovy$115
- Ozempic$111
How this compares
$52,572 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,196 | $1,316,156 |
| EntrestoSacubitril/Valsartan | 390 | $429,320 |
| XareltoRivaroxaban | 308 | $306,128 |
| JardianceEmpagliflozin | 221 | $214,678 |
| MultaqDronedarone Hcl | 86 | $100,827 |
| FarxigaDapagliflozin Propanediol | 89 | $80,278 |
| BrilintaTicagrelor | 61 | $47,614 |
| Repatha SureclickEvolocumab | 32 | $26,760 |
| Repatha SyringeEvolocumab | 33 | $23,162 |
| VerquvoVericiguat | 20 | $22,550 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 60 | $21,091 |
| Metoprolol Succinate | 1,063 | $15,808 |
| VascepaIcosapent Ethyl | 15 | $14,523 |
| Atorvastatin Calcium | 1,256 | $12,157 |
| Ranolazine ErRanolazine | 82 | $10,341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $449 | $1,316,1561,196 claims |
| NovartisEntresto | $555 | $429,320390 claims |
| Johnson & JohnsonXarelto | $260 | $306,128308 claims |
| Boehringer IngelheimJardiance | $350 | $214,678221 claims |
| AstraZenecaFarxiga, Brilinta | $463 | $127,892150 claims |
| Sanofi-aventis U.S. LLCMultaq | $348 | $100,82786 claims |
| MerckVerquvo | $409 | $22,55020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Vero Beach
- Vijay HaryaniVero Beach$413K
- Raghavendra Charan MakamVero Beach$110K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.